DermatologyResearch Phase

Haloxyl (Chrysin + Palmitoyl Peptides)

Topical

Overview

Haloxyl is a combination ingredient consisting of chrysin, a naturally occurring flavone, and palmitoyl oligopeptides designed to address periorbital hyperpigmentation and edema. The chrysin component is thought to activate enzyme systems involved in bilirubin and hemoglobin clearance, while the palmitoyl peptides enhance dermal penetration and stimulate lymphatic drainage.

Mechanism of Action

This dual-mechanism approach targets the appearance of dark circles attributable to both vascular congestion and iron deposition..

Research Summary & Key Findings

Manufacturer-sponsored studies reported reductions in periorbital pigmentation and puffiness assessed by chromametry and clinical grading, though independent replication in peer-reviewed dermatology literature is limited. The evidence base consists primarily of in vitro permeability studies and small open-label human trials without published long-term safety data.

Clinical Status

Research Phase

Haloxyl (Chrysin + Palmitoyl Peptides) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

Related Peptides in Dermatology

Find a Provider

Find a verified provider who offers Haloxyl (Chrysin + Palmitoyl Peptides) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Haloxyl (Chrysin + Palmitoyl Peptides).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.